Another current example of theranostics that evoked strong clinical interest was the management of breast cancer targeting human epidermal growth factor receptor type 2 (HER2) wherein the quantitative PET navigates the anti-HER2 targeting chemotherapy with antibody-based pharmaceuticals. Here, ERBB2 is linked to breast carcinoma.